Labopharm CEO steps down as biotech launches strategic review; Dendreon's chief scientist to retire;

@FierceBiotech: Roche, Novartis make MIT innovators list. Item | Follow @FierceBiotech

> Canada's Labopharm CEO James Howard Tripp has made an abrupt and unexplained departure from the biotech, opening the door for CFO Mark D'Souza. Labopharm also said that it's beginning a complete review of its strategic options. Story

Xconomy is reporting that David Urdal, Dendreon's chief scientist and a key mover behind the development of the world's first approved cancer immunotherapy, plans to retire by the end of this year. Report

Pharma News

> Wockhardt's shares down on winding-up petition acceptance. Story

> Study: Statins may reduce prostate cancer risk. Article

> Court overturns two patents for Cephalon painkiller. News

> Legal challenges on branded drug patents way up. Item

> Lilly animal health unit offers to buy Janssen outfit. Report

Biotech IT News

> Researchers get a jump on NCI trials group revamp. Item

> Biogen Idec arthritis model gets personal. Report

> PPDI develops portal to hold volunteers. Item 

> Integration, joint trials will speed approvals. Article 

> Cold call symbolizes CIO scourge: tech marketing. Story

> Biopsies trump imaging in cancer-spread trial. News

Medical Device News

> FDA says no to Medtronic's Amplify. News

> Edwards Lifesciences completes $43M Embrella buy. Story

> Breathe Technologies looks to move HQ to OC. Item

> Boston Sci, St. Jude settle breach-of-contract dispute. Article

> FDA OKs Covidien's LEU-based isotope production‎. Report

> Medtronic opens manufacturing facility in Singapore. Item

And Finally... Are women more easily addicted to cocaine than men? New research published in BioMed Central's open access journal Biology of Sex Differences reinforces this position by showing that the motivation of female rats to work for cocaine is much higher than males. News

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.